이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Jiangsu Aidea Pharmaceutical 관리

관리 기준 확인 4/4

Jiangsu Aidea Pharmaceutical's CEO는 Heliang Fu, Jan2016 에 임명되었습니다 의 임기는 8.42 년입니다. 는 CN¥ 166.20M 가치에 해당하는 회사 주식의 3.13% 직접 소유합니다. 166.20M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 5.1 년입니다.

주요 정보

Heliang Fu

최고 경영자

CN¥680.3k

총 보상

CEO 급여 비율	n/a
CEO 임기	8.4yrs
CEO 소유권	3.1%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	5.1yrs

최근 관리 업데이트

Recent updates

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jun 29

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Jun 07

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Mar 01

CEO

Heliang Fu (62 yo)

8.4yrs

테뉴어

CN¥680,300

보상

Mr. Heliang Fu serves as Chairman of the Board at Jiangsu Aidea Pharmaceutical Co. Ltd since 2014 and serves as its Chief Executive Officer since February 19, 2019 and also serves as its President since 20...

리더십 팀

이름	위치	테뉴어	보상	소유권
Heliang Fu	Chairman	8.4yrs	CN¥680.30k	3.13% CN¥ 134.7m
Ke Yu	VP, CFO and Director	3.8yrs	CN¥1.68m	0.0037% CN¥ 157.4k
Jun Wang	VP & Director	5.3yrs	CN¥910.50k	0.66% CN¥ 28.3m
Rongrong Wu	VP & Chief Medical Officer	5.3yrs	CN¥676.10k	1.3% CN¥ 55.9m
Jing Zhang	Senior Vice President	2.4yrs	CN¥3.77m	데이터 없음
Qi Hong	Senior Vice President	2.4yrs	CN¥1.13m	데이터 없음
Guang Rong Wang	VP & Director	1.3yrs	CN¥916.20k	0.016% CN¥ 698.4k
Jie Zhang	Executive Vice President	1.2yrs	데이터 없음	데이터 없음
Hong Qin	Vice President	1.2yrs	데이터 없음	데이터 없음
Yan Liu	Secretary of the Board	1.2yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: 688488 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Heliang Fu	Chairman	10.4yrs	CN¥680.30k	3.13% CN¥ 134.7m
Ke Yu	VP, CFO and Director	3.8yrs	CN¥1.68m	0.0037% CN¥ 157.4k
Jun Wang	VP & Director	5.3yrs	CN¥910.50k	0.66% CN¥ 28.3m
Guang Rong Wang	VP & Director	5.3yrs	CN¥916.20k	0.016% CN¥ 698.4k
Heng Yu	Chairman of the Supervisory Board	3.8yrs	데이터 없음	1.2% CN¥ 51.8m
Lin Fang Song	Supervisor	5.3yrs	데이터 없음	데이터 없음
Yu Quan Wei	Independent Director	5.1yrs	CN¥100.00k	데이터 없음
Feng Ying He	Supervisor	3.8yrs	데이터 없음	데이터 없음
Guang Ji Wang	Independent Director	5.1yrs	CN¥100.00k	데이터 없음
Chang Qing Zhang	Independent Director	5.1yrs	CN¥100.00k	데이터 없음
Xiao Yan Qi	Independent Director	2.3yrs	CN¥100.00k	데이터 없음

5.1yrs

평균 재임 기간

48yo

평균 연령

경험이 풍부한 이사회: 688488 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.

Jiangsu Aidea Pharmaceutical 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Less than half of directors are independent

Recent updates

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) 30% Share Price Plunge Could Signal Some Risk

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Jiangsu Aidea Pharmaceutical (SHSE:688488) Is Making Moderate Use Of Debt

Full year 2023 earnings released: CN¥0.18 loss per share (vs CN¥0.30 loss in FY 2022)

Jiangsu Aidea Pharmaceutical Co., Ltd., Annual General Meeting, May 13, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Shares Climb 27% But Its Business Is Yet to Catch Up

Full year 2023 earnings released: CN¥0.19 loss per share (vs CN¥0.30 loss in FY 2022)

Second quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0.11 loss in 2Q 2022)

New major risk - Share price stability

Jiangsu Aidea Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 22, 2023

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Full year 2022 earnings released: CN¥0.29 loss per share (vs CN¥0.07 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.02 loss per share (vs CN¥0.045 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.11 loss per share (vs CN¥0.003 profit in 2Q 2021)

Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) agreed to acquire 19.9646% stake in Nanjing Nanda Pharmaceutical Co., Ltd. from Jiangsu Sheng Feng Medical Technology Company Limited for CNY 86 million.

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.03 profit in 1Q 2021)

Full year 2021 earnings released: CN¥0.07 loss per share (vs CN¥0.10 profit in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: CN¥0.045 loss per share (vs CN¥0.014 profit in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.053 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.03 (vs CN¥0.01 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.10 (vs CN¥0.09 in FY 2019)

New 90-day low: CN¥19.66

New 90-day low: CN¥19.86

New 90-day low: CN¥26.00

New 90-day low: CN¥26.80

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령